We are live on ! Find out more
ROIV icon

Roivant Sciences

337 hedge funds and large institutions have $7.59B invested in Roivant Sciences in 2025 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 125 increasing their positions, 95 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

157% more call options, than puts

Call options by funds: $114M | Put options by funds: $44.4M

32% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 95

31% more capital invested

Capital invested by funds: $5.8B → $7.59B (+$1.79B)

15% more funds holding in top 10

Funds holding in top 10: 1315 (+2)

5% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 56

0% more funds holding

Funds holding: 337337 (0)

2.23% less ownership

Funds ownership: 75.68%73.45% (-2.2%)

Holders
337
Holders Change
Holders Change %
0%
% of All Funds
4.42%
Holding in Top 10
15
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+15.38%
% of All Funds
0.2%
New
59
Increased
125
Reduced
95
Closed
56
Calls
$114M
Puts
$44.4M
Net Calls
+$69.6M
Net Calls Change
-$6.8M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$919M +$65.1M +5,257,703 +9%
Morgan Stanley
2
Morgan Stanley
New York
$671M -$4.59M -371,109 -0.8%
SIAU
3
SB Investment Advisers (UK)
United Kingdom
$610M -$243M -19,637,525 -33%
BlackRock
4
BlackRock
New York
$601M -$7.32M -591,428 -1%
Vanguard Group
5
Vanguard Group
Pennsylvania
$587M -$6.45M -521,408 -1%
QF
6
QVT Financial
New York
$445M
Viking Global Investors
7
Viking Global Investors
Connecticut
$357M -$132M -10,642,948 -31%
RCMNY
8
Rubric Capital Management (New York)
New York
$303M -$4.58M -370,336 -2%
State Street
9
State Street
Massachusetts
$283M -$13.3M -1,073,336 -5%
PSC
10
Patient Square Capital
California
$189M
TSC
11
Two Seas Capital
New York
$178M +$14.3M +1,156,124 +11%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$141M +$17.6M +1,423,074 +18%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$124M +$5.6M +452,195 +6%
PA
14
Perceptive Advisors
New York
$111M +$50M +4,036,996 +121%
Adage Capital Partners
15
Adage Capital Partners
Massachusetts
$109M +$63.8M +5,150,000 +247%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$70.1M +$1.54M +124,548 +3%
BCP
17
BlackBarn Capital Partners
New York
$66.6M -$2.79M -225,000 -5%
SC
18
Stempoint Capital
New York
$63.5M +$44.5M +3,595,406 +597%
Marshall Wace
19
Marshall Wace
United Kingdom
$60.2M +$37.4M +3,022,851 +316%
BBA
20
Baker Bros. Advisors
New York
$57M
WCM
21
Whitefort Capital Management
New York
$53.4M -$4.33M -350,000 -9%
ACM
22
ADAR1 Capital Management
Texas
$50.6M +$17.4M +1,406,704 +72%
Northern Trust
23
Northern Trust
Illinois
$49.7M +$617K +49,847 +2%
SI
24
Sofinnova Investments
California
$47.6M +$748K +60,456 +2%
Charles Schwab
25
Charles Schwab
California
$47.2M +$2.83M +228,649 +8%

ROIV Hedge Fund Activity: Q3 2025 in Review

337 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q3 2025, worth a combined $7.59B — up 31% from $5.8B a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new ROIV positions and 56 closed out — a net gain of 3 holders — while 125 added to existing stakes and 95 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $65.1M. The largest seller was SB Investment Advisers (UK), cutting an estimated $243M.

  • 337 institutional investors held Roivant Sciences (ROIV) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $7.59B of Roivant Sciences stock for Q3 2025, up 31% quarter-over-quarter.
  • 59 funds opened new Roivant Sciences positions in Q3 2025 and 56 closed out, a net change of +3 holders.
  • The largest Roivant Sciences buyer in Q3 2025 was Fidelity Investments, an estimated $65.1M added.
  • The largest Roivant Sciences seller in Q3 2025 was SB Investment Advisers (UK), an estimated $243M sold.

Based on aggregated 13F filings for Q3 2025.